nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—DDC—pineal body—multiple sclerosis	0.02	0.087	CbGeAlD
L-DOPA—DDC—nerve—multiple sclerosis	0.0145	0.0632	CbGeAlD
L-DOPA—Mimosine—CCL2—multiple sclerosis	0.0111	0.671	CrCbGaD
L-DOPA—PSIP1—brainstem—multiple sclerosis	0.0109	0.0476	CbGeAlD
L-DOPA—DRD1—nerve—multiple sclerosis	0.0107	0.0464	CbGeAlD
L-DOPA—PSIP1—retina—multiple sclerosis	0.0106	0.0459	CbGeAlD
L-DOPA—PSIP1—medulla oblongata—multiple sclerosis	0.00763	0.0332	CbGeAlD
L-DOPA—PSIP1—midbrain—multiple sclerosis	0.00697	0.0303	CbGeAlD
L-DOPA—PSIP1—spinal cord—multiple sclerosis	0.0068	0.0296	CbGeAlD
L-DOPA—DRD2—nerve—multiple sclerosis	0.00631	0.0274	CbGeAlD
L-DOPA—DDC—brainstem—multiple sclerosis	0.00624	0.0271	CbGeAlD
L-DOPA—PSIP1—nervous system—multiple sclerosis	0.00573	0.0249	CbGeAlD
L-DOPA—PSIP1—central nervous system—multiple sclerosis	0.00552	0.024	CbGeAlD
L-DOPA—PSIP1—cerebellum—multiple sclerosis	0.0054	0.0234	CbGeAlD
L-DOPA—SLC7A5—retina—multiple sclerosis	0.00539	0.0234	CbGeAlD
L-DOPA—DRD1—brainstem—multiple sclerosis	0.00458	0.0199	CbGeAlD
L-DOPA—PSIP1—brain—multiple sclerosis	0.00438	0.019	CbGeAlD
L-DOPA—DDC—midbrain—multiple sclerosis	0.00398	0.0173	CbGeAlD
L-DOPA—Isoprenaline—MAPK1—multiple sclerosis	0.00392	0.237	CrCbGaD
L-DOPA—SLC7A5—medulla oblongata—multiple sclerosis	0.0039	0.0169	CbGeAlD
L-DOPA—SLC7A8—nervous system—multiple sclerosis	0.00378	0.0164	CbGeAlD
L-DOPA—DRD4—brain—multiple sclerosis	0.00365	0.0159	CbGeAlD
L-DOPA—SLC7A8—central nervous system—multiple sclerosis	0.00364	0.0158	CbGeAlD
L-DOPA—SLC7A5—midbrain—multiple sclerosis	0.00356	0.0155	CbGeAlD
L-DOPA—SLC7A8—cerebellum—multiple sclerosis	0.00356	0.0155	CbGeAlD
L-DOPA—SLC7A5—spinal cord—multiple sclerosis	0.00348	0.0151	CbGeAlD
L-DOPA—DRD3—nervous system—multiple sclerosis	0.00335	0.0146	CbGeAlD
L-DOPA—DDC—nervous system—multiple sclerosis	0.00327	0.0142	CbGeAlD
L-DOPA—DRD3—central nervous system—multiple sclerosis	0.00323	0.014	CbGeAlD
L-DOPA—DDC—central nervous system—multiple sclerosis	0.00315	0.0137	CbGeAlD
L-DOPA—DRD5—nervous system—multiple sclerosis	0.00314	0.0137	CbGeAlD
L-DOPA—DRD5—central nervous system—multiple sclerosis	0.00303	0.0132	CbGeAlD
L-DOPA—SLC7A5—nervous system—multiple sclerosis	0.00293	0.0127	CbGeAlD
L-DOPA—DRD1—midbrain—multiple sclerosis	0.00292	0.0127	CbGeAlD
L-DOPA—SLC7A8—brain—multiple sclerosis	0.00289	0.0126	CbGeAlD
L-DOPA—SLC7A5—central nervous system—multiple sclerosis	0.00282	0.0123	CbGeAlD
L-DOPA—SLC7A5—cerebellum—multiple sclerosis	0.00276	0.012	CbGeAlD
L-DOPA—DRD2—brainstem—multiple sclerosis	0.00271	0.0118	CbGeAlD
L-DOPA—DRD2—retina—multiple sclerosis	0.00261	0.0114	CbGeAlD
L-DOPA—DRD3—brain—multiple sclerosis	0.00256	0.0111	CbGeAlD
L-DOPA—DDC—brain—multiple sclerosis	0.0025	0.0109	CbGeAlD
L-DOPA—DRD5—brain—multiple sclerosis	0.0024	0.0104	CbGeAlD
L-DOPA—DRD1—nervous system—multiple sclerosis	0.0024	0.0104	CbGeAlD
L-DOPA—DRD1—central nervous system—multiple sclerosis	0.00231	0.0101	CbGeAlD
L-DOPA—SLC7A5—brain—multiple sclerosis	0.00224	0.00973	CbGeAlD
L-DOPA—SLC16A10—cerebellum—multiple sclerosis	0.00211	0.00917	CbGeAlD
L-DOPA—SLC7A5—Desoximetasone—Methylprednisolone—multiple sclerosis	0.00192	0.174	CbGdCrCtD
L-DOPA—SLC7A5—Desoximetasone—Betamethasone—multiple sclerosis	0.00189	0.172	CbGdCrCtD
L-DOPA—SLC7A5—Desoximetasone—Dexamethasone—multiple sclerosis	0.00189	0.172	CbGdCrCtD
L-DOPA—SLC7A5—Desoximetasone—Triamcinolone—multiple sclerosis	0.00185	0.168	CbGdCrCtD
L-DOPA—DRD1—brain—multiple sclerosis	0.00184	0.00798	CbGeAlD
L-DOPA—SLC7A5—Desoximetasone—Prednisone—multiple sclerosis	0.00176	0.159	CbGdCrCtD
L-DOPA—DRD2—midbrain—multiple sclerosis	0.00173	0.0075	CbGeAlD
L-DOPA—SLC7A5—Desoximetasone—Prednisolone—multiple sclerosis	0.00171	0.155	CbGdCrCtD
L-DOPA—CYP2D6—brainstem—multiple sclerosis	0.00163	0.00707	CbGeAlD
L-DOPA—DRD2—nervous system—multiple sclerosis	0.00142	0.00617	CbGeAlD
L-DOPA—DRD2—central nervous system—multiple sclerosis	0.00137	0.00594	CbGeAlD
L-DOPA—DRD2—cerebellum—multiple sclerosis	0.00134	0.0058	CbGeAlD
L-DOPA—DRD2—brain—multiple sclerosis	0.00108	0.00471	CbGeAlD
L-DOPA—Epinephrine—TNF—multiple sclerosis	0.000931	0.0563	CrCbGaD
L-DOPA—CYP2D6—nervous system—multiple sclerosis	0.000853	0.00371	CbGeAlD
L-DOPA—CYP2D6—central nervous system—multiple sclerosis	0.000821	0.00357	CbGeAlD
L-DOPA—CYP2D6—cerebellum—multiple sclerosis	0.000802	0.00349	CbGeAlD
L-DOPA—CYP2D6—brain—multiple sclerosis	0.000652	0.00283	CbGeAlD
L-DOPA—Liothyronine—ALB—multiple sclerosis	0.000589	0.0356	CrCbGaD
L-DOPA—Angioedema—Methylprednisolone—multiple sclerosis	0.000564	0.00136	CcSEcCtD
L-DOPA—Haemorrhage—Prednisone—multiple sclerosis	0.000562	0.00135	CcSEcCtD
L-DOPA—Hallucination—Prednisone—multiple sclerosis	0.000559	0.00135	CcSEcCtD
L-DOPA—Malaise—Triamcinolone—multiple sclerosis	0.000558	0.00134	CcSEcCtD
L-DOPA—Malaise—Methylprednisolone—multiple sclerosis	0.000557	0.00134	CcSEcCtD
L-DOPA—Syncope—Triamcinolone—multiple sclerosis	0.000555	0.00134	CcSEcCtD
L-DOPA—Syncope—Methylprednisolone—multiple sclerosis	0.000554	0.00133	CcSEcCtD
L-DOPA—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000552	0.00133	CcSEcCtD
L-DOPA—Oedema—Prednisolone—multiple sclerosis	0.000549	0.00132	CcSEcCtD
L-DOPA—Dizziness—Azathioprine—multiple sclerosis	0.000548	0.00132	CcSEcCtD
L-DOPA—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000548	0.00132	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000545	0.00131	CcSEcCtD
L-DOPA—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000544	0.00131	CcSEcCtD
L-DOPA—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000543	0.00131	CcSEcCtD
L-DOPA—Shock—Prednisolone—multiple sclerosis	0.00054	0.0013	CcSEcCtD
L-DOPA—Cough—Triamcinolone—multiple sclerosis	0.00054	0.0013	CcSEcCtD
L-DOPA—Convulsion—Triamcinolone—multiple sclerosis	0.000536	0.00129	CcSEcCtD
L-DOPA—Convulsion—Methylprednisolone—multiple sclerosis	0.000535	0.00129	CcSEcCtD
L-DOPA—Hypertension—Triamcinolone—multiple sclerosis	0.000534	0.00129	CcSEcCtD
L-DOPA—Hypertension—Methylprednisolone—multiple sclerosis	0.000533	0.00128	CcSEcCtD
L-DOPA—Urticaria—Mitoxantrone—multiple sclerosis	0.000532	0.00128	CcSEcCtD
L-DOPA—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000531	0.00128	CcSEcCtD
L-DOPA—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000529	0.00127	CcSEcCtD
L-DOPA—Vomiting—Azathioprine—multiple sclerosis	0.000527	0.00127	CcSEcCtD
L-DOPA—Anxiety—Methylprednisolone—multiple sclerosis	0.000524	0.00126	CcSEcCtD
L-DOPA—Rash—Azathioprine—multiple sclerosis	0.000522	0.00126	CcSEcCtD
L-DOPA—Dermatitis—Azathioprine—multiple sclerosis	0.000522	0.00126	CcSEcCtD
L-DOPA—Depression—Methotrexate—multiple sclerosis	0.000522	0.00126	CcSEcCtD
L-DOPA—Flushing—Prednisone—multiple sclerosis	0.000521	0.00126	CcSEcCtD
L-DOPA—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000521	0.00126	CcSEcCtD
L-DOPA—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000521	0.00126	CcSEcCtD
L-DOPA—Discomfort—Triamcinolone—multiple sclerosis	0.000521	0.00125	CcSEcCtD
L-DOPA—Discomfort—Methylprednisolone—multiple sclerosis	0.000519	0.00125	CcSEcCtD
L-DOPA—Headache—Azathioprine—multiple sclerosis	0.000519	0.00125	CcSEcCtD
L-DOPA—Dry mouth—Triamcinolone—multiple sclerosis	0.000515	0.00124	CcSEcCtD
L-DOPA—Angioedema—Dexamethasone—multiple sclerosis	0.000513	0.00124	CcSEcCtD
L-DOPA—Angioedema—Betamethasone—multiple sclerosis	0.000513	0.00124	CcSEcCtD
L-DOPA—Confusional state—Methylprednisolone—multiple sclerosis	0.000508	0.00122	CcSEcCtD
L-DOPA—Malaise—Betamethasone—multiple sclerosis	0.000506	0.00122	CcSEcCtD
L-DOPA—Malaise—Dexamethasone—multiple sclerosis	0.000506	0.00122	CcSEcCtD
L-DOPA—Oedema—Triamcinolone—multiple sclerosis	0.000505	0.00122	CcSEcCtD
L-DOPA—Syncope—Dexamethasone—multiple sclerosis	0.000504	0.00121	CcSEcCtD
L-DOPA—Syncope—Betamethasone—multiple sclerosis	0.000504	0.00121	CcSEcCtD
L-DOPA—Arrhythmia—Prednisone—multiple sclerosis	0.000502	0.00121	CcSEcCtD
L-DOPA—Shock—Triamcinolone—multiple sclerosis	0.000497	0.0012	CcSEcCtD
L-DOPA—Insomnia—Prednisolone—multiple sclerosis	0.000497	0.0012	CcSEcCtD
L-DOPA—Alopecia—Prednisone—multiple sclerosis	0.000496	0.0012	CcSEcCtD
L-DOPA—Shock—Methylprednisolone—multiple sclerosis	0.000496	0.00119	CcSEcCtD
L-DOPA—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000494	0.00119	CcSEcCtD
L-DOPA—Loss of consciousness—Betamethasone—multiple sclerosis	0.000494	0.00119	CcSEcCtD
L-DOPA—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000493	0.00119	CcSEcCtD
L-DOPA—Paraesthesia—Prednisolone—multiple sclerosis	0.000493	0.00119	CcSEcCtD
L-DOPA—Mental disorder—Prednisone—multiple sclerosis	0.000492	0.00119	CcSEcCtD
L-DOPA—Nausea—Azathioprine—multiple sclerosis	0.000492	0.00118	CcSEcCtD
L-DOPA—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000488	0.00118	CcSEcCtD
L-DOPA—Agranulocytosis—Methotrexate—multiple sclerosis	0.000488	0.00118	CcSEcCtD
L-DOPA—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000487	0.00117	CcSEcCtD
L-DOPA—Convulsion—Betamethasone—multiple sclerosis	0.000487	0.00117	CcSEcCtD
L-DOPA—Convulsion—Dexamethasone—multiple sclerosis	0.000487	0.00117	CcSEcCtD
L-DOPA—Hypertension—Dexamethasone—multiple sclerosis	0.000485	0.00117	CcSEcCtD
L-DOPA—Hypertension—Betamethasone—multiple sclerosis	0.000485	0.00117	CcSEcCtD
L-DOPA—Asthenia—Mitoxantrone—multiple sclerosis	0.00048	0.00116	CcSEcCtD
L-DOPA—Anxiety—Dexamethasone—multiple sclerosis	0.000476	0.00115	CcSEcCtD
L-DOPA—Anxiety—Betamethasone—multiple sclerosis	0.000476	0.00115	CcSEcCtD
L-DOPA—Discomfort—Dexamethasone—multiple sclerosis	0.000472	0.00114	CcSEcCtD
L-DOPA—Discomfort—Betamethasone—multiple sclerosis	0.000472	0.00114	CcSEcCtD
L-DOPA—Haemoglobin—Methotrexate—multiple sclerosis	0.000472	0.00114	CcSEcCtD
L-DOPA—Hypotension—Methylprednisolone—multiple sclerosis	0.000471	0.00113	CcSEcCtD
L-DOPA—Pain—Prednisolone—multiple sclerosis	0.00047	0.00113	CcSEcCtD
L-DOPA—Haemorrhage—Methotrexate—multiple sclerosis	0.00047	0.00113	CcSEcCtD
L-DOPA—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000464	0.00112	CcSEcCtD
L-DOPA—Vision blurred—Prednisone—multiple sclerosis	0.000461	0.00111	CcSEcCtD
L-DOPA—Urethral disorder—Methotrexate—multiple sclerosis	0.00046	0.00111	CcSEcCtD
L-DOPA—Oedema—Dexamethasone—multiple sclerosis	0.000458	0.0011	CcSEcCtD
L-DOPA—Oedema—Betamethasone—multiple sclerosis	0.000458	0.0011	CcSEcCtD
L-DOPA—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000458	0.0011	CcSEcCtD
L-DOPA—Insomnia—Triamcinolone—multiple sclerosis	0.000457	0.0011	CcSEcCtD
L-DOPA—Insomnia—Methylprednisolone—multiple sclerosis	0.000456	0.0011	CcSEcCtD
L-DOPA—Ill-defined disorder—Prednisone—multiple sclerosis	0.000454	0.00109	CcSEcCtD
L-DOPA—Paraesthesia—Triamcinolone—multiple sclerosis	0.000454	0.00109	CcSEcCtD
L-DOPA—Feeling abnormal—Prednisolone—multiple sclerosis	0.000453	0.00109	CcSEcCtD
L-DOPA—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000453	0.00109	CcSEcCtD
L-DOPA—Anaemia—Prednisone—multiple sclerosis	0.000452	0.00109	CcSEcCtD
L-DOPA—Shock—Betamethasone—multiple sclerosis	0.000451	0.00109	CcSEcCtD
L-DOPA—Shock—Dexamethasone—multiple sclerosis	0.000451	0.00109	CcSEcCtD
L-DOPA—Dyspnoea—Triamcinolone—multiple sclerosis	0.00045	0.00108	CcSEcCtD
L-DOPA—Agitation—Prednisone—multiple sclerosis	0.000449	0.00108	CcSEcCtD
L-DOPA—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000449	0.00108	CcSEcCtD
L-DOPA—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000449	0.00108	CcSEcCtD
L-DOPA—Angioedema—Prednisone—multiple sclerosis	0.000447	0.00108	CcSEcCtD
L-DOPA—Dyspepsia—Triamcinolone—multiple sclerosis	0.000445	0.00107	CcSEcCtD
L-DOPA—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000444	0.00107	CcSEcCtD
L-DOPA—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000443	0.00107	CcSEcCtD
L-DOPA—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000443	0.00107	CcSEcCtD
L-DOPA—Malaise—Prednisone—multiple sclerosis	0.000441	0.00106	CcSEcCtD
L-DOPA—Syncope—Prednisone—multiple sclerosis	0.000439	0.00106	CcSEcCtD
L-DOPA—Anorexia—Dexamethasone—multiple sclerosis	0.000437	0.00105	CcSEcCtD
L-DOPA—Anorexia—Betamethasone—multiple sclerosis	0.000437	0.00105	CcSEcCtD
L-DOPA—Urticaria—Prednisolone—multiple sclerosis	0.000436	0.00105	CcSEcCtD
L-DOPA—Fatigue—Triamcinolone—multiple sclerosis	0.000436	0.00105	CcSEcCtD
L-DOPA—Fatigue—Methylprednisolone—multiple sclerosis	0.000435	0.00105	CcSEcCtD
L-DOPA—Pain—Triamcinolone—multiple sclerosis	0.000432	0.00104	CcSEcCtD
L-DOPA—Loss of consciousness—Prednisone—multiple sclerosis	0.00043	0.00104	CcSEcCtD
L-DOPA—Hypotension—Betamethasone—multiple sclerosis	0.000428	0.00103	CcSEcCtD
L-DOPA—Hypotension—Dexamethasone—multiple sclerosis	0.000428	0.00103	CcSEcCtD
L-DOPA—Vomiting—Mitoxantrone—multiple sclerosis	0.000426	0.00103	CcSEcCtD
L-DOPA—Convulsion—Prednisone—multiple sclerosis	0.000424	0.00102	CcSEcCtD
L-DOPA—Hypertension—Prednisone—multiple sclerosis	0.000422	0.00102	CcSEcCtD
L-DOPA—Rash—Mitoxantrone—multiple sclerosis	0.000422	0.00102	CcSEcCtD
L-DOPA—Dermatitis—Mitoxantrone—multiple sclerosis	0.000422	0.00102	CcSEcCtD
L-DOPA—Headache—Mitoxantrone—multiple sclerosis	0.000419	0.00101	CcSEcCtD
L-DOPA—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000416	0.001	CcSEcCtD
L-DOPA—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000415	0.001	CcSEcCtD
L-DOPA—Anxiety—Prednisone—multiple sclerosis	0.000415	0.000999	CcSEcCtD
L-DOPA—Alopecia—Methotrexate—multiple sclerosis	0.000415	0.000999	CcSEcCtD
L-DOPA—Insomnia—Dexamethasone—multiple sclerosis	0.000415	0.000999	CcSEcCtD
L-DOPA—Insomnia—Betamethasone—multiple sclerosis	0.000415	0.000999	CcSEcCtD
L-DOPA—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000412	0.000993	CcSEcCtD
L-DOPA—Paraesthesia—Dexamethasone—multiple sclerosis	0.000412	0.000991	CcSEcCtD
L-DOPA—Paraesthesia—Betamethasone—multiple sclerosis	0.000412	0.000991	CcSEcCtD
L-DOPA—Discomfort—Prednisone—multiple sclerosis	0.000411	0.000991	CcSEcCtD
L-DOPA—Mental disorder—Methotrexate—multiple sclerosis	0.000411	0.000991	CcSEcCtD
L-DOPA—Hypersensitivity—Prednisolone—multiple sclerosis	0.000405	0.000975	CcSEcCtD
L-DOPA—Dyspepsia—Dexamethasone—multiple sclerosis	0.000403	0.000972	CcSEcCtD
L-DOPA—Dyspepsia—Betamethasone—multiple sclerosis	0.000403	0.000972	CcSEcCtD
L-DOPA—Urticaria—Triamcinolone—multiple sclerosis	0.000401	0.000967	CcSEcCtD
L-DOPA—Urticaria—Methylprednisolone—multiple sclerosis	0.0004	0.000964	CcSEcCtD
L-DOPA—Dysgeusia—Methotrexate—multiple sclerosis	0.0004	0.000964	CcSEcCtD
L-DOPA—Oedema—Prednisone—multiple sclerosis	0.000399	0.000961	CcSEcCtD
L-DOPA—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000398	0.00096	CcSEcCtD
L-DOPA—Decreased appetite—Betamethasone—multiple sclerosis	0.000398	0.00096	CcSEcCtD
L-DOPA—Decreased appetite—Dexamethasone—multiple sclerosis	0.000398	0.00096	CcSEcCtD
L-DOPA—Nausea—Mitoxantrone—multiple sclerosis	0.000398	0.000958	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000396	0.000953	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000396	0.000953	CcSEcCtD
L-DOPA—Back pain—Methotrexate—multiple sclerosis	0.000395	0.000952	CcSEcCtD
L-DOPA—Fatigue—Betamethasone—multiple sclerosis	0.000395	0.000952	CcSEcCtD
L-DOPA—Fatigue—Dexamethasone—multiple sclerosis	0.000395	0.000952	CcSEcCtD
L-DOPA—Shock—Prednisone—multiple sclerosis	0.000393	0.000946	CcSEcCtD
L-DOPA—Pain—Betamethasone—multiple sclerosis	0.000392	0.000944	CcSEcCtD
L-DOPA—Pain—Dexamethasone—multiple sclerosis	0.000392	0.000944	CcSEcCtD
L-DOPA—Hyperhidrosis—Prednisone—multiple sclerosis	0.000386	0.000929	CcSEcCtD
L-DOPA—Vision blurred—Methotrexate—multiple sclerosis	0.000385	0.000928	CcSEcCtD
L-DOPA—Anorexia—Prednisone—multiple sclerosis	0.00038	0.000916	CcSEcCtD
L-DOPA—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000379	0.000913	CcSEcCtD
L-DOPA—Anaemia—Methotrexate—multiple sclerosis	0.000378	0.00091	CcSEcCtD
L-DOPA—Feeling abnormal—Betamethasone—multiple sclerosis	0.000378	0.00091	CcSEcCtD
L-DOPA—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000378	0.00091	CcSEcCtD
L-DOPA—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000375	0.000903	CcSEcCtD
L-DOPA—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000375	0.000903	CcSEcCtD
L-DOPA—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000372	0.000896	CcSEcCtD
L-DOPA—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000371	0.000894	CcSEcCtD
L-DOPA—Malaise—Methotrexate—multiple sclerosis	0.000369	0.000888	CcSEcCtD
L-DOPA—Leukopenia—Methotrexate—multiple sclerosis	0.000366	0.000881	CcSEcCtD
L-DOPA—Urticaria—Dexamethasone—multiple sclerosis	0.000364	0.000877	CcSEcCtD
L-DOPA—Urticaria—Betamethasone—multiple sclerosis	0.000364	0.000877	CcSEcCtD
L-DOPA—Dizziness—Prednisolone—multiple sclerosis	0.000363	0.000875	CcSEcCtD
L-DOPA—Asthenia—Triamcinolone—multiple sclerosis	0.000362	0.000873	CcSEcCtD
L-DOPA—Abdominal pain—Betamethasone—multiple sclerosis	0.000362	0.000873	CcSEcCtD
L-DOPA—Abdominal pain—Dexamethasone—multiple sclerosis	0.000362	0.000873	CcSEcCtD
L-DOPA—Asthenia—Methylprednisolone—multiple sclerosis	0.000362	0.000871	CcSEcCtD
L-DOPA—Insomnia—Prednisone—multiple sclerosis	0.000361	0.00087	CcSEcCtD
L-DOPA—Paraesthesia—Prednisone—multiple sclerosis	0.000358	0.000863	CcSEcCtD
L-DOPA—Pruritus—Triamcinolone—multiple sclerosis	0.000357	0.000861	CcSEcCtD
L-DOPA—Cough—Methotrexate—multiple sclerosis	0.000357	0.000859	CcSEcCtD
L-DOPA—Pruritus—Methylprednisolone—multiple sclerosis	0.000357	0.000859	CcSEcCtD
L-DOPA—Convulsion—Methotrexate—multiple sclerosis	0.000354	0.000853	CcSEcCtD
L-DOPA—Dyspepsia—Prednisone—multiple sclerosis	0.000351	0.000846	CcSEcCtD
L-DOPA—Chest pain—Methotrexate—multiple sclerosis	0.000348	0.000838	CcSEcCtD
L-DOPA—Decreased appetite—Prednisone—multiple sclerosis	0.000347	0.000836	CcSEcCtD
L-DOPA—Rash—Prednisolone—multiple sclerosis	0.000346	0.000834	CcSEcCtD
L-DOPA—Dermatitis—Prednisolone—multiple sclerosis	0.000346	0.000833	CcSEcCtD
L-DOPA—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000345	0.000831	CcSEcCtD
L-DOPA—Fatigue—Prednisone—multiple sclerosis	0.000344	0.000829	CcSEcCtD
L-DOPA—Headache—Prednisolone—multiple sclerosis	0.000344	0.000829	CcSEcCtD
L-DOPA—Discomfort—Methotrexate—multiple sclerosis	0.000344	0.000828	CcSEcCtD
L-DOPA—Constipation—Prednisone—multiple sclerosis	0.000341	0.000822	CcSEcCtD
L-DOPA—Confusional state—Methotrexate—multiple sclerosis	0.000336	0.00081	CcSEcCtD
L-DOPA—Dizziness—Triamcinolone—multiple sclerosis	0.000334	0.000805	CcSEcCtD
L-DOPA—Dizziness—Methylprednisolone—multiple sclerosis	0.000333	0.000803	CcSEcCtD
L-DOPA—Feeling abnormal—Prednisone—multiple sclerosis	0.000329	0.000792	CcSEcCtD
L-DOPA—Asthenia—Dexamethasone—multiple sclerosis	0.000329	0.000792	CcSEcCtD
L-DOPA—Asthenia—Betamethasone—multiple sclerosis	0.000329	0.000792	CcSEcCtD
L-DOPA—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000327	0.000787	CcSEcCtD
L-DOPA—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000326	0.000786	CcSEcCtD
L-DOPA—Nausea—Prednisolone—multiple sclerosis	0.000326	0.000786	CcSEcCtD
L-DOPA—Pruritus—Dexamethasone—multiple sclerosis	0.000324	0.000781	CcSEcCtD
L-DOPA—Pruritus—Betamethasone—multiple sclerosis	0.000324	0.000781	CcSEcCtD
L-DOPA—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000322	0.000777	CcSEcCtD
L-DOPA—Vomiting—Triamcinolone—multiple sclerosis	0.000321	0.000774	CcSEcCtD
L-DOPA—Vomiting—Methylprednisolone—multiple sclerosis	0.00032	0.000772	CcSEcCtD
L-DOPA—Rash—Triamcinolone—multiple sclerosis	0.000319	0.000767	CcSEcCtD
L-DOPA—Dermatitis—Triamcinolone—multiple sclerosis	0.000318	0.000766	CcSEcCtD
L-DOPA—Anorexia—Methotrexate—multiple sclerosis	0.000318	0.000766	CcSEcCtD
L-DOPA—Rash—Methylprednisolone—multiple sclerosis	0.000318	0.000765	CcSEcCtD
L-DOPA—Dermatitis—Methylprednisolone—multiple sclerosis	0.000318	0.000765	CcSEcCtD
L-DOPA—Urticaria—Prednisone—multiple sclerosis	0.000317	0.000764	CcSEcCtD
L-DOPA—Headache—Triamcinolone—multiple sclerosis	0.000316	0.000762	CcSEcCtD
L-DOPA—Headache—Methylprednisolone—multiple sclerosis	0.000316	0.000761	CcSEcCtD
L-DOPA—Abdominal pain—Prednisone—multiple sclerosis	0.000316	0.00076	CcSEcCtD
L-DOPA—Diarrhoea—Betamethasone—multiple sclerosis	0.000314	0.000755	CcSEcCtD
L-DOPA—Diarrhoea—Dexamethasone—multiple sclerosis	0.000314	0.000755	CcSEcCtD
L-DOPA—Hypotension—Methotrexate—multiple sclerosis	0.000312	0.000751	CcSEcCtD
L-DOPA—Dizziness—Dexamethasone—multiple sclerosis	0.000303	0.00073	CcSEcCtD
L-DOPA—Dizziness—Betamethasone—multiple sclerosis	0.000303	0.00073	CcSEcCtD
L-DOPA—Insomnia—Methotrexate—multiple sclerosis	0.000302	0.000727	CcSEcCtD
L-DOPA—Nausea—Triamcinolone—multiple sclerosis	0.0003	0.000723	CcSEcCtD
L-DOPA—Paraesthesia—Methotrexate—multiple sclerosis	0.0003	0.000722	CcSEcCtD
L-DOPA—Nausea—Methylprednisolone—multiple sclerosis	0.000299	0.000721	CcSEcCtD
L-DOPA—Dyspnoea—Methotrexate—multiple sclerosis	0.000297	0.000716	CcSEcCtD
L-DOPA—Somnolence—Methotrexate—multiple sclerosis	0.000297	0.000714	CcSEcCtD
L-DOPA—Hypersensitivity—Prednisone—multiple sclerosis	0.000294	0.000708	CcSEcCtD
L-DOPA—Dyspepsia—Methotrexate—multiple sclerosis	0.000294	0.000707	CcSEcCtD
L-DOPA—Vomiting—Dexamethasone—multiple sclerosis	0.000291	0.000702	CcSEcCtD
L-DOPA—Vomiting—Betamethasone—multiple sclerosis	0.000291	0.000702	CcSEcCtD
L-DOPA—Decreased appetite—Methotrexate—multiple sclerosis	0.00029	0.000698	CcSEcCtD
L-DOPA—Rash—Betamethasone—multiple sclerosis	0.000289	0.000696	CcSEcCtD
L-DOPA—Rash—Dexamethasone—multiple sclerosis	0.000289	0.000696	CcSEcCtD
L-DOPA—Dermatitis—Betamethasone—multiple sclerosis	0.000289	0.000695	CcSEcCtD
L-DOPA—Dermatitis—Dexamethasone—multiple sclerosis	0.000289	0.000695	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000288	0.000694	CcSEcCtD
L-DOPA—Fatigue—Methotrexate—multiple sclerosis	0.000288	0.000693	CcSEcCtD
L-DOPA—Headache—Dexamethasone—multiple sclerosis	0.000287	0.000692	CcSEcCtD
L-DOPA—Headache—Betamethasone—multiple sclerosis	0.000287	0.000692	CcSEcCtD
L-DOPA—Asthenia—Prednisone—multiple sclerosis	0.000286	0.00069	CcSEcCtD
L-DOPA—Pain—Methotrexate—multiple sclerosis	0.000285	0.000687	CcSEcCtD
L-DOPA—Pruritus—Prednisone—multiple sclerosis	0.000282	0.00068	CcSEcCtD
L-DOPA—Feeling abnormal—Methotrexate—multiple sclerosis	0.000275	0.000662	CcSEcCtD
L-DOPA—Diarrhoea—Prednisone—multiple sclerosis	0.000273	0.000658	CcSEcCtD
L-DOPA—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000273	0.000657	CcSEcCtD
L-DOPA—Nausea—Dexamethasone—multiple sclerosis	0.000272	0.000656	CcSEcCtD
L-DOPA—Nausea—Betamethasone—multiple sclerosis	0.000272	0.000656	CcSEcCtD
L-DOPA—Urticaria—Methotrexate—multiple sclerosis	0.000265	0.000638	CcSEcCtD
L-DOPA—Dizziness—Prednisone—multiple sclerosis	0.000264	0.000636	CcSEcCtD
L-DOPA—Abdominal pain—Methotrexate—multiple sclerosis	0.000264	0.000635	CcSEcCtD
L-DOPA—Vomiting—Prednisone—multiple sclerosis	0.000254	0.000611	CcSEcCtD
L-DOPA—Rash—Prednisone—multiple sclerosis	0.000252	0.000606	CcSEcCtD
L-DOPA—Dermatitis—Prednisone—multiple sclerosis	0.000251	0.000606	CcSEcCtD
L-DOPA—Headache—Prednisone—multiple sclerosis	0.00025	0.000602	CcSEcCtD
L-DOPA—Hypersensitivity—Methotrexate—multiple sclerosis	0.000246	0.000592	CcSEcCtD
L-DOPA—Asthenia—Methotrexate—multiple sclerosis	0.000239	0.000577	CcSEcCtD
L-DOPA—Nausea—Prednisone—multiple sclerosis	0.000237	0.000571	CcSEcCtD
L-DOPA—Pruritus—Methotrexate—multiple sclerosis	0.000236	0.000568	CcSEcCtD
L-DOPA—Diarrhoea—Methotrexate—multiple sclerosis	0.000228	0.00055	CcSEcCtD
L-DOPA—Dizziness—Methotrexate—multiple sclerosis	0.000221	0.000531	CcSEcCtD
L-DOPA—Vomiting—Methotrexate—multiple sclerosis	0.000212	0.000511	CcSEcCtD
L-DOPA—Rash—Methotrexate—multiple sclerosis	0.00021	0.000507	CcSEcCtD
L-DOPA—Dermatitis—Methotrexate—multiple sclerosis	0.00021	0.000506	CcSEcCtD
L-DOPA—Headache—Methotrexate—multiple sclerosis	0.000209	0.000503	CcSEcCtD
L-DOPA—Nausea—Methotrexate—multiple sclerosis	0.000198	0.000477	CcSEcCtD
L-DOPA—DRD1—Signaling by GPCR—CCR2—multiple sclerosis	0.000102	0.000312	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GPR65—multiple sclerosis	0.000101	0.000309	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SRM—multiple sclerosis	0.000101	0.000309	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CCR2—multiple sclerosis	0.000101	0.000308	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCL3—multiple sclerosis	0.000101	0.000307	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—POMC—multiple sclerosis	0.0001	0.000307	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	9.95e-05	0.000304	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CCR5—multiple sclerosis	9.92e-05	0.000303	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—POMC—multiple sclerosis	9.9e-05	0.000303	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CCL2—multiple sclerosis	9.82e-05	0.0003	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—ALB—multiple sclerosis	9.79e-05	0.000299	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL2RA—multiple sclerosis	9.77e-05	0.000299	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	9.73e-05	0.000297	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CCR5—multiple sclerosis	9.69e-05	0.000296	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CCL2—multiple sclerosis	9.69e-05	0.000296	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTGER4—multiple sclerosis	9.68e-05	0.000296	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—S1PR1—multiple sclerosis	9.6e-05	0.000293	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PGR—multiple sclerosis	9.53e-05	0.000291	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CXCL10—multiple sclerosis	9.44e-05	0.000288	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CNR1—multiple sclerosis	9.44e-05	0.000288	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCR1—multiple sclerosis	9.37e-05	0.000286	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL13—multiple sclerosis	9.37e-05	0.000286	CbGpPWpGaD
L-DOPA—CYP2D6—Biological oxidations—POMC—multiple sclerosis	9.37e-05	0.000286	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CXCL10—multiple sclerosis	9.36e-05	0.000286	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCR3—multiple sclerosis	9.34e-05	0.000286	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GPC5—multiple sclerosis	9.34e-05	0.000285	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CNR1—multiple sclerosis	9.31e-05	0.000285	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CD28—multiple sclerosis	9.26e-05	0.000283	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCR1—multiple sclerosis	9.25e-05	0.000283	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL13—multiple sclerosis	9.25e-05	0.000283	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CXCL10—multiple sclerosis	9.23e-05	0.000282	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCR2—multiple sclerosis	9.09e-05	0.000278	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—IL6—multiple sclerosis	9.06e-05	0.000277	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PTGER4—multiple sclerosis	9.05e-05	0.000277	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CCL5—multiple sclerosis	8.95e-05	0.000273	CbGpPWpGaD
L-DOPA—PSIP1—Disease—IL6—multiple sclerosis	8.88e-05	0.000271	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCR3—multiple sclerosis	8.74e-05	0.000267	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCL3—multiple sclerosis	8.54e-05	0.000261	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—POMC—multiple sclerosis	8.53e-05	0.000261	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CCR2—multiple sclerosis	8.5e-05	0.00026	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCL10—multiple sclerosis	8.5e-05	0.00026	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CNR1—multiple sclerosis	8.39e-05	0.000256	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCL10—multiple sclerosis	8.38e-05	0.000256	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PTGER4—multiple sclerosis	8.22e-05	0.000251	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RGS1—multiple sclerosis	8.16e-05	0.000249	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—IL6—multiple sclerosis	8.16e-05	0.000249	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CCL5—multiple sclerosis	8.12e-05	0.000248	CbGpPWpGaD
L-DOPA—DDC—Metabolism—APOE—multiple sclerosis	8.11e-05	0.000248	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CCR5—multiple sclerosis	8.06e-05	0.000246	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CCL5—multiple sclerosis	8.05e-05	0.000246	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—IL6—multiple sclerosis	8.05e-05	0.000246	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CCL5—multiple sclerosis	7.95e-05	0.000243	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—IL2RA—multiple sclerosis	7.94e-05	0.000243	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCR3—multiple sclerosis	7.94e-05	0.000243	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CNR1—multiple sclerosis	7.84e-05	0.00024	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—POMC—multiple sclerosis	7.75e-05	0.000237	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GPR65—multiple sclerosis	7.74e-05	0.000236	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCR2—multiple sclerosis	7.72e-05	0.000236	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CCL2—multiple sclerosis	7.58e-05	0.000232	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—POMC—multiple sclerosis	7.58e-05	0.000232	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCL10—multiple sclerosis	7.55e-05	0.000231	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCL3—multiple sclerosis	7.42e-05	0.000227	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CCL2—multiple sclerosis	7.41e-05	0.000227	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CCR5—multiple sclerosis	7.32e-05	0.000224	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CCL5—multiple sclerosis	7.31e-05	0.000224	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CCR5—multiple sclerosis	7.26e-05	0.000222	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CCL5—multiple sclerosis	7.22e-05	0.000221	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL2RA—multiple sclerosis	7.21e-05	0.00022	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CCR5—multiple sclerosis	7.16e-05	0.000219	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—IL2RA—multiple sclerosis	7.15e-05	0.000219	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTGER4—multiple sclerosis	7.14e-05	0.000218	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CNR1—multiple sclerosis	7.12e-05	0.000218	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	7.12e-05	0.000218	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	7.12e-05	0.000218	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL13—multiple sclerosis	7.08e-05	0.000216	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCR1—multiple sclerosis	7.08e-05	0.000216	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL10—multiple sclerosis	7.06e-05	0.000216	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—IL2RA—multiple sclerosis	7.06e-05	0.000216	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PGR—multiple sclerosis	7.03e-05	0.000215	CbGpPWpGaD
L-DOPA—DDC—Metabolism—POMC—multiple sclerosis	6.97e-05	0.000213	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCR3—multiple sclerosis	6.9e-05	0.000211	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—TYK2—multiple sclerosis	6.89e-05	0.00021	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CD28—multiple sclerosis	6.83e-05	0.000209	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCR2—multiple sclerosis	6.71e-05	0.000205	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCL3—multiple sclerosis	6.68e-05	0.000204	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CD86—multiple sclerosis	6.6e-05	0.000202	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCL3—multiple sclerosis	6.59e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CCR5—multiple sclerosis	6.59e-05	0.000201	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GPC5—multiple sclerosis	6.51e-05	0.000199	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCL5—multiple sclerosis	6.5e-05	0.000199	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CCR5—multiple sclerosis	6.5e-05	0.000199	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL2RA—multiple sclerosis	6.49e-05	0.000198	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTGER4—multiple sclerosis	6.43e-05	0.000196	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL10—multiple sclerosis	6.41e-05	0.000196	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL2RA—multiple sclerosis	6.41e-05	0.000196	CbGpPWpGaD
L-DOPA—DDC—Metabolism—ALB—multiple sclerosis	6.35e-05	0.000194	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTGER4—multiple sclerosis	6.34e-05	0.000194	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PGR—multiple sclerosis	6.33e-05	0.000193	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—IL2—multiple sclerosis	6.31e-05	0.000193	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—POMC—multiple sclerosis	6.3e-05	0.000193	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PGR—multiple sclerosis	6.25e-05	0.000191	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCR3—multiple sclerosis	6.21e-05	0.00019	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CNR1—multiple sclerosis	6.19e-05	0.000189	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—IL6—multiple sclerosis	6.16e-05	0.000188	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CD28—multiple sclerosis	6.15e-05	0.000188	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCR3—multiple sclerosis	6.13e-05	0.000187	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CCL5—multiple sclerosis	6.08e-05	0.000186	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CD28—multiple sclerosis	6.07e-05	0.000185	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCR2—multiple sclerosis	6.04e-05	0.000185	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SPP1—multiple sclerosis	6.02e-05	0.000184	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCR2—multiple sclerosis	5.96e-05	0.000182	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCR5—multiple sclerosis	5.86e-05	0.000179	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL2RA—multiple sclerosis	5.77e-05	0.000176	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL2—multiple sclerosis	5.73e-05	0.000175	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—POMC—multiple sclerosis	5.72e-05	0.000175	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—POMC—multiple sclerosis	5.67e-05	0.000173	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CCL2—multiple sclerosis	5.6e-05	0.000171	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—POMC—multiple sclerosis	5.59e-05	0.000171	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL10—multiple sclerosis	5.57e-05	0.00017	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CNR1—multiple sclerosis	5.57e-05	0.00017	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCL5—multiple sclerosis	5.52e-05	0.000169	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CNR1—multiple sclerosis	5.5e-05	0.000168	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CCR5—multiple sclerosis	5.48e-05	0.000167	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—IL2RA—multiple sclerosis	5.4e-05	0.000165	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—RRM1—multiple sclerosis	5.4e-05	0.000165	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—APOE—multiple sclerosis	5.33e-05	0.000163	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—POMC—multiple sclerosis	5.15e-05	0.000157	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—TYK2—multiple sclerosis	5.08e-05	0.000155	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—POMC—multiple sclerosis	5.08e-05	0.000155	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL3—multiple sclerosis	5.04e-05	0.000154	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CCL2—multiple sclerosis	5.04e-05	0.000154	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL10—multiple sclerosis	5.02e-05	0.000153	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCR5—multiple sclerosis	4.97e-05	0.000152	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CCL2—multiple sclerosis	4.97e-05	0.000152	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL10—multiple sclerosis	4.95e-05	0.000151	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL2RA—multiple sclerosis	4.9e-05	0.00015	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CD86—multiple sclerosis	4.87e-05	0.000149	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTGER4—multiple sclerosis	4.85e-05	0.000148	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CD80—multiple sclerosis	4.82e-05	0.000147	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCL5—multiple sclerosis	4.8e-05	0.000147	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PGR—multiple sclerosis	4.78e-05	0.000146	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCR3—multiple sclerosis	4.69e-05	0.000143	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—IL2—multiple sclerosis	4.66e-05	0.000142	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CD28—multiple sclerosis	4.64e-05	0.000142	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—POMC—multiple sclerosis	4.58e-05	0.00014	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—TYK2—multiple sclerosis	4.57e-05	0.00014	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCR2—multiple sclerosis	4.56e-05	0.000139	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—TYK2—multiple sclerosis	4.51e-05	0.000138	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCL2—multiple sclerosis	4.48e-05	0.000137	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SPP1—multiple sclerosis	4.44e-05	0.000136	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CD86—multiple sclerosis	4.39e-05	0.000134	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—MAPK1—multiple sclerosis	4.38e-05	0.000134	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CD86—multiple sclerosis	4.33e-05	0.000132	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCR5—multiple sclerosis	4.32e-05	0.000132	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCL5—multiple sclerosis	4.32e-05	0.000132	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—POMC—multiple sclerosis	4.28e-05	0.000131	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCL5—multiple sclerosis	4.26e-05	0.00013	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL2RA—multiple sclerosis	4.26e-05	0.00013	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL2—multiple sclerosis	4.23e-05	0.000129	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CNR1—multiple sclerosis	4.21e-05	0.000129	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—IL2—multiple sclerosis	4.19e-05	0.000128	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—IL2—multiple sclerosis	4.14e-05	0.000126	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TYK2—multiple sclerosis	4.07e-05	0.000124	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SPP1—multiple sclerosis	4e-05	0.000122	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SPP1—multiple sclerosis	3.95e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APOE—multiple sclerosis	3.93e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCR5—multiple sclerosis	3.89e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—POMC—multiple sclerosis	3.89e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCR5—multiple sclerosis	3.84e-05	0.000117	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL2RA—multiple sclerosis	3.84e-05	0.000117	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL2—multiple sclerosis	3.81e-05	0.000116	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCL2—multiple sclerosis	3.8e-05	0.000116	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL10—multiple sclerosis	3.79e-05	0.000116	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL2RA—multiple sclerosis	3.78e-05	0.000116	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL2—multiple sclerosis	3.76e-05	0.000115	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CD80—multiple sclerosis	3.56e-05	0.000109	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APOE—multiple sclerosis	3.54e-05	0.000108	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APOE—multiple sclerosis	3.49e-05	0.000107	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—TYK2—multiple sclerosis	3.45e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL2—multiple sclerosis	3.38e-05	0.000103	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—POMC—multiple sclerosis	3.38e-05	0.000103	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL6—multiple sclerosis	3.37e-05	0.000103	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CD86—multiple sclerosis	3.31e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCL2—multiple sclerosis	3.31e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL5—multiple sclerosis	3.26e-05	9.97e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—MAPK1—multiple sclerosis	3.23e-05	9.89e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MMP9—multiple sclerosis	3.2e-05	9.79e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CD80—multiple sclerosis	3.2e-05	9.78e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—IL2—multiple sclerosis	3.16e-05	9.67e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CD80—multiple sclerosis	3.16e-05	9.65e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—BCHE—multiple sclerosis	3.1e-05	9.47e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—POMC—multiple sclerosis	3.04e-05	9.3e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SPP1—multiple sclerosis	3.02e-05	9.23e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TYK2—multiple sclerosis	3e-05	9.17e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—POMC—multiple sclerosis	3e-05	9.17e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCL2—multiple sclerosis	2.98e-05	9.1e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCR5—multiple sclerosis	2.94e-05	8.98e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCL2—multiple sclerosis	2.94e-05	8.97e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—MAPK1—multiple sclerosis	2.91e-05	8.9e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL2RA—multiple sclerosis	2.9e-05	8.85e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL2—multiple sclerosis	2.87e-05	8.78e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—MAPK1—multiple sclerosis	2.87e-05	8.78e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—STAT3—multiple sclerosis	2.85e-05	8.7e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TYK2—multiple sclerosis	2.7e-05	8.26e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOE—multiple sclerosis	2.67e-05	8.17e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TYK2—multiple sclerosis	2.67e-05	8.15e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MYC—multiple sclerosis	2.65e-05	8.09e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TGFB1—multiple sclerosis	2.64e-05	8.07e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK1—multiple sclerosis	2.59e-05	7.91e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL2—multiple sclerosis	2.5e-05	7.63e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL6—multiple sclerosis	2.49e-05	7.6e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CD80—multiple sclerosis	2.42e-05	7.39e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP9—multiple sclerosis	2.36e-05	7.23e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—POMC—multiple sclerosis	2.3e-05	7.02e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL2—multiple sclerosis	2.25e-05	6.87e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL2—multiple sclerosis	2.25e-05	6.87e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6—multiple sclerosis	2.24e-05	6.84e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL2—multiple sclerosis	2.22e-05	6.78e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6—multiple sclerosis	2.21e-05	6.75e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—MAPK1—multiple sclerosis	2.2e-05	6.72e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP9—multiple sclerosis	2.13e-05	6.5e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—STAT3—multiple sclerosis	2.1e-05	6.42e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP9—multiple sclerosis	2.1e-05	6.42e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TYK2—multiple sclerosis	2.04e-05	6.24e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6—multiple sclerosis	1.99e-05	6.08e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MYC—multiple sclerosis	1.95e-05	5.97e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TGFB1—multiple sclerosis	1.95e-05	5.96e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK1—multiple sclerosis	1.91e-05	5.84e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STAT3—multiple sclerosis	1.89e-05	5.78e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STAT3—multiple sclerosis	1.87e-05	5.71e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOE—multiple sclerosis	1.86e-05	5.7e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MYC—multiple sclerosis	1.76e-05	5.37e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TGFB1—multiple sclerosis	1.75e-05	5.36e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MYC—multiple sclerosis	1.73e-05	5.3e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TGFB1—multiple sclerosis	1.73e-05	5.29e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK1—multiple sclerosis	1.72e-05	5.26e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL2—multiple sclerosis	1.7e-05	5.19e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK1—multiple sclerosis	1.7e-05	5.19e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6—multiple sclerosis	1.69e-05	5.16e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP9—multiple sclerosis	1.61e-05	4.91e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—POMC—multiple sclerosis	1.6e-05	4.9e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6—multiple sclerosis	1.47e-05	4.49e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALB—multiple sclerosis	1.46e-05	4.46e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STAT3—multiple sclerosis	1.43e-05	4.37e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MYC—multiple sclerosis	1.33e-05	4.06e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TGFB1—multiple sclerosis	1.32e-05	4.05e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6—multiple sclerosis	1.32e-05	4.04e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6—multiple sclerosis	1.3e-05	3.99e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK1—multiple sclerosis	1.3e-05	3.97e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6—multiple sclerosis	9.98e-06	3.05e-05	CbGpPWpGaD
